

IN THE CLAIMS:

Amend the claims as follows.

Claims 1-44. (Canceled).

45. (New) A kit of parts comprising a first container and a second container,
said first container comprising an antibody molecule conjugated to a first
lipase component having a first lipase activity, and
said second container comprising a liposome containing one or more
pharmaceutically active compound and a second lipase component having a second
lipase activity,
said first lipase component and said second lipase component
reconstituting to form a third lipase component having a third lipase activity, said third
lipase activity being greater than the sum of said first lipase activity and said second
lipase activity,
wherein said first lipase component is a N-terminal recombinant
Clostridium perfringens α -toxin (N-CPAT) and said second lipase component is a C-
terminal recombinant *Clostridium perfringens* α -toxin (C-CPAT),
said third lipase activity being sufficient to release said one or more
pharmaceutically active compound from said liposome when said third lipase
component is contacted with said liposome.

46. (New) The kit of parts of claim 45 wherein said first lipase component is a N-CPAT and said second lipase component is a C-CPAT, and said N-CPAT and said C-CPAT do conjoin to form said third lipase component.

47. (New) A kit of parts comprising a first container and a second container,
said first container comprising an antibody molecule conjugated to a first lipase component having a first lipase activity, and

said second container comprising a liposome containing one or more pharmaceutically active compound and a second lipase component having a second lipase activity,

said first lipase component and said second lipase component reconstituting to form a third lipase component having a third lipase activity, said third lipase activity being greater than the sum of said first lipase activity and said second lipase activity,

wherein said second lipase component is a N-terminal recombinant *Clostridium perfringens* α -toxin (N-CPAT) and said first lipase component is a C-terminal recombinant *Clostridium perfringens* α -toxin (C-CPAT),

said third lipase activity being sufficient to release said one or more pharmaceutically active compound from said liposome when said third lipase component is contacted with said liposome.

48. (New) The kit of parts of any one of claims 45 and 47 wherein said antibody molecule specifically binds to a target selected from the group consisting of an antigen, an antigen presenting target cell and a nucleotide sequence.

49. (New) The kit of parts of claim 48 wherein said antigen presenting target cell is a tumor cell.

50. (New) The kit of parts of any one of claims 45 and 47 wherein said pharmaceutically active compound is selected from the group consisting of a chemotherapeutic cytotoxic agent, a lymphokine, an anti-inflammatory agent, an anti-fungal agent, and an anti-malaria agent.